# Enter your 510(k) Summary or Statement.

510(k) Summary

Per 21 CFR §807.92

<table><tr><td rowspan=1 colspan=1>Date Prepared:</td><td rowspan=1 colspan=1>October 16, 2008</td></tr><tr><td rowspan=1 colspan=1>Company</td><td rowspan=1 colspan=1>Abbott Laboratories</td></tr><tr><td rowspan=1 colspan=1>Division</td><td rowspan=1 colspan=1>Abbott Diabetes Care Inc.</td></tr><tr><td rowspan=1 colspan=1>Street Address</td><td rowspan=1 colspan=1>1360 South Loop Road</td></tr><tr><td rowspan=1 colspan=1>City, State Zip</td><td rowspan=1 colspan=1>Alameda, CA 94502</td></tr><tr><td rowspan=1 colspan=1>Telephone No.</td><td rowspan=1 colspan=1>510-749-5400</td></tr><tr><td rowspan=1 colspan=1>Fax No.</td><td rowspan=1 colspan=1>510-864-4791</td></tr><tr><td rowspan=1 colspan=1>Contact Person:</td><td rowspan=1 colspan=1>Arul SterlinTel No. 510-864-4310Fax No. 510-864-4791arul.sterlin@abbott.com</td></tr><tr><td rowspan=1 colspan=1>Proprietary Name:</td><td rowspan=1 colspan=1>ReliOn Ultima Advance Blood Glucose MonitoringSystem</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Common Name:</td><td rowspan=1 colspan=1>Blood Glucose Testing System</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Classification Name:</td><td rowspan=1 colspan=1>Glucose Dehydrogenase, Glucose, Class II (21 CFR§862.1345)Product codes: NBW, LFR,Single Analyte Control Solution, Class I(21 CFR§ 862.1660)Product code: JJX</td><td></td></tr><tr><td rowspan=1 colspan=1>Predicate Device:</td><td rowspan=1 colspan=1>Optium Plus Blood Glucose Test Strips and PrecisionXtra Plus Blood Glucose Test Strips (K051213)</td><td rowspan=1 colspan=1>.</td></tr></table>

# Description of the Device:

TelUtloo luoste UBoGu BoGucT n uBo Gu   oy

TlUv BlGust usy uvalen ne tology esshe reicyseelUt system utilizes amperometric biosensor technology to measure current generated on disposable test strips.

v Xtra Plus Blood Glucose Test Strips, (K051213. The test stripsanfacturing procss isunchange and allhe u   uB teRelva Guc g e dinucleotide (GDH-NAD) as co-factor.

l instructed to calibrate their meter each time they open and use a new box of test strips.

TRlnUltvae proa w reeiltinet nde equirement for the user to insert a calibration bar into the meter.

Abbott Diabetes Care, Inc. c/o Mr. Arul Sterlin Regulatory Affairs Associate 1360 South Loop Road Alameda, CA 94502

# NOV 2 6 2008

Re: k081975 Trade/Device Name: ReliOn Ultima Advance Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose Test System Regulatory Class: II Product Code: NBW, LFR, JJX Dated: October 24, 2008 Received: October 27, 2008

Dear Mr. Sterlin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in thc enclosure) to legally marketed predicate devices markcted in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmctic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This leter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M.Coopes, M.S., DVM.

# Indication for Use

510(k) Number (if known): K081975

Device Name: ReliOn Ultima Advance Blood Glucose Monitoring System

Indication For Use:

The ReliOn Ultima Advance Blood Glucose Monitoring System is intended for in-vitro diagnostic use in the quantitative measurement of glucose in fresh whole blood for selftesting by lay users (e.g., from the finger, forearm, upper arm or base of thumb), or by health care professionals. It is not intended to be used for testing neonatal blood samples. The ReliOn Ultima Advance system is indicated for home (lay user) or professional use in the management of patients with diabetes.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/b70e862f905a7afce4eeeee1c0d2987b1516e709d044a8f8b833f56d23a43a12.jpg)  
Page 1 of 2

Divisiqn Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k) k081975